ArticleACS central science2015
The use of
Abstract read
In one paragraph
Article in ACS central science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- PET imaging of HIV-1 envelope protein gp120 usingiScience · 2025Article
- The Future of TCR-like Antibodies in Diagnosis and Potential Application Targets.Current molecular medicine · 2025Review
- Sortase-Mediated Site-Specific Conjugation to Prepare Fluorine-18-Labeled Nanobodies.Bioconjugate chemistry · 2024Article
- Claudin18.2-Targeted SPECT/CT Imaging for Gastric Cancer: Preclinical Evaluation and Clinical Translation of theACS pharmacology & translational science · 2024Article
- SyntheticRSC medicinal chemistry · 2024Review
- Development of a Stable Peptide-Major Histocompatibility Complex (MHC) via Sortase and Click Chemistry.ACS pharmacology & translational science · 2024Article
- Nanobody-based CAR NK cells for possible immunotherapy of MICAPNAS nexus · 2024Article
- MICA-specific nanobodies for diagnosis and immunotherapy of MICAFrontiers in immunology · 2024Article
- Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy.Immunotherapy advances · 2024Review
- Article
- Small Antibodies with Big Applications: Nanobody-Based Cancer Diagnostics and Therapeutics.Cancers · 2023Review
- In Vivo Biorthogonal Antibody Click for Dual Targeting and Augmented Efficacy in Cancer Treatment.bioRxiv : the preprint server for biology · 2023Article
- Click chemistry: a transformative technology in nuclear medicine.Nature protocols · 2023Review
- Synthesis, Fluorine-18 Radiolabeling, and In Vivo PET Imaging of a Hydrophilic Fluorosulfotetrazine.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Preclinical evaluation of [European journal of nuclear medicine and molecular imaging · 2022Article
- Activation of a G protein-coupled receptor through indirect antibody-mediated tethering of ligands.RSC chemical biology · 2021Article
- Sweetening Pharmaceutical Radiochemistry byPharmaceuticals (Basel, Switzerland) · 2021Review
- Converting an Anti-Mouse CD4 Monoclonal Antibody into an scFv Positron Emission Tomography Imaging Agent for Longitudinal Monitoring of CD4Journal of immunology (Baltimore, Md. : 1950) · 2021Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Mohammad RashidianWhitehead Institute for Biomedical Research, Cambridge, MA 02142; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142.
Edmund KeliherCenter for Systems Biology Department, Massachusetts General Hospital, 185 Cambridge St., Boston, MA 02114 (USA).
Michael DouganWhitehead Institute for Biomedical Research, Cambridge, MA 02142; Department of Gastroenterology, Massachusetts General Hospital Boston, 185 Cambridge St., MA 02114.
Patrick K JurasWhitehead Institute for Biomedical Research, Cambridge, MA 02142.
Marco CavallariWhitehead Institute for Biomedical Research, Cambridge, MA 02142.
Gregory R WojtkiewiczCenter for Systems Biology Department, Massachusetts General Hospital, 185 Cambridge St., Boston, MA 02114 (USA).
Johanne JacobsenWhitehead Institute for Biomedical Research, Cambridge, MA 02142.
Jerre G EdensWhitehead Institute for Biomedical Research, Cambridge, MA 02142.
Jeroen M G TasWhitehead Institute for Biomedical Research, Cambridge, MA 02142.
Gabriel VictoraWhitehead Institute for Biomedical Research, Cambridge, MA 02142.
Ralph WeisslederCenter for Systems Biology Department, Massachusetts General Hospital, 185 Cambridge St., Boston, MA 02114 (USA); Department of Systems Biology, Harvard Medical School 200 Longwood Ave, Boston, MA 02115.
Hidde PloeghWhitehead Institute for Biomedical Research, Cambridge, MA 02142; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142.
Funding
The RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7MStatisticsP50CA086355 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2015
$27.8MA new strategy to disrupt protein-protein interactions in eukaryotic cells.DP1GM106409 · NIGMS · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI PLOEGH, HIDDE L. · 2012 to 2016
$4.8MSortase-mediated protein engineering for the study of host-pathogen interactionsR01AI087879 · NIAID · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI PLOEGH, HIDDE L. · 2010 to 2019
$4.5MNovel Clickdyes for Biomedical SensingR01EB010011 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2010 to 2017
$3.1MEndosomal TLRs and their accessory proteins: cell biology and biochemistryR01GM100518 · NIGMS · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI PLOEGH, HIDDE L. · 2012 to 2015
$1.5MNon-invasive imaging of the immune response based on the use of isotopically labeled single domain antibody fragmentsR21AI117373 · NIAID · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI PLOEGH, HIDDE L. · 2015 to 2016
$536kNCI NIH HHS P01 CA117969NCI NIH HHS P50 CA086355NIAID NIH HHS R01 AI087879NIAID NIH HHS R21 AI117373NIBIB NIH HHS R01 EB010011NIGMS NIH HHS DP1 GM106409NIGMS NIH HHS R01 GM100518
Abstract
We generated
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.